Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Oppenheimer Remains Bullish on Geron Corp (GERN) Following Two Articles in NEJM
September 3, 2015 11:06 AM EDTOppenheimer reiterated an Outperform rating and $5.50 price target on Geron Corporation (NASDAQ: GERN) following the publication of two articles in the New England Journal of Medicine (NEJM). The article highlight the company's flagship compound imetelstat for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).... More
Geron Corp (GERN) Announces Publication of Two Papers in NEJM Highlighting Imetelstat
September 2, 2015 5:04 PM EDTGeron Corp (Nasdaq: GERN) announced the publication of two papers in The New England Journal of Medicine (NEJM) in which the companys telomerase inhibitor, imetelstat, was shown to have disease-modifying activity thought to be associated with selective inhibition of the malignant progenitor cell clones responsible for the underlying disease in two hematologic myeloid malignancies, essential thrombocythemia (ET) and myelofibrosis (MF). The papers are available online in the September 3rd issue at www.NEJM.org.
The data in the ET and MF study publications in The New England Journal of Medicine provide compelling... More
